Method for the prevention of hospital infection in Saint Petersburg

Abstract

BACKGROUND: Cystic fibrosis is one of the most frequent monogenic diseases, in which, in addition to medical measures, measures for the prevention of the infectious process in the lungs are of great importance, which is provided by a clear organization of the work of any medical institution where patients are observed and where medical and rehabilitation measures are carried out.

AIM: The article describes the experience of the children’s Center in St. Petersburg to prevent cross-infection of patients with cystic fibrosis who have the different luge microbiome.

MATERIALS AND METHODS: The measures taken included a system for monitoring and dynamic control of the seeded pathogenic microflora with a strict separation of patients with cystic fibrosis, who had the isolation and carriage of various pathogens. The system provided for the separation of flows of patients with cystic fibrosis and the prevention of cross-infection, as well as a number of activities related to the disinfection of equipment.

RESULTS: The methods adopted and put into practice have ensured the prevention of cross-infection of patients with cystic fibrosis, excreting various pathogenic bacteria from sputum. The patient management system made it possible to halve the number of hospitalizations of patients with Pseudomonas aeruginosa infection per CF patient per year: from 1.3 in 2001 to 0.6 in 2021, reduce the risk of cross-infection, reduce the number of relapses, hospitalizations and the average length of stay of a patient in a hospital.

CONCLUSIONS: The developed system of assistance has shown its effectiveness and can be implemented in one form or another in the work of cystic fibrosis treatment centers in the Russian Federation.

Keywords

cystic fibrosis in children / prevention of cystic fibrosis / cross-infection / disinfection in cystic fibrosis

References

[1] Shaginyan IA, Kapranov NI, Chernuxa MYu, et al. Microbial population of lower respiratory tract in children from different age groups with cystic fibrosis. Zh Mikrobiol Epidemiol Immunobiol. 2010;(1):15–20. (In Russ.)

[2] Шагинян И.А., Капранов Н.И., Чернуха М.Ю. и др. Микробный пейзаж нижних дыхательных путей у различных возрастных групп детей, больных муковисцидозом // Журнал микробиологии, эпидемиологии и инфекционных болезней. 2010. № 1. С. 15–20.

[3] Polikarpova SV, Zhilina SV, Kondratenko OV, et al. Rukovodstvo po mikrobiologicheskoi diagnostike infektsii dykhatel’nykh putei u patsientov s mukovistsidozom. Moscow; 2019. (In Russ.)

[4] Поликарпова С.В., Жилина С.В., Кондратенко О.В. и др. Руководство по микробиологической диагностике инфекций дыхательных путей у пациентов с муковисцидозом. Москва, 2019.

[5] Totton N, Bradburn M, Hoo ZH, et al. Prospectively predicting Pseudomonas aeruginosa infection’s using routine data from the UK cystic fibrosis register. Health Sci Rep. 2021;4(4):e381. DOI: 10.1002/hsr2.381

[6] Totton N., Bradburn M., Hoo Z.H. et al. Prospectively predicting Pseudomonas aeruginosa infection’s using routine data from the UK cystic fibrosis register // Health Sci. Rep. 2021. Vol. 4, No. 4. P. e381. DOI: 10.1002/hsr2.381

[7] Huse HK, Lee MJ, Wootton M, et al. Evaluation of antimicrobial susceptibility testing methods for burkholderia cenocepacia and burkholderia multivorans isolates from cystic fibrosis patients. J Clin Microbiol. 2021;59(12):e0144721. DOI: 10.1128/JCM.01447-21

[8] Huse H.K., Lee M.J., Wootton M. et al. Evaluation of antimicrobial susceptibility testing methods for burkholderia cenocepacia and burkholderia multivorans isolates from cystic fibrosis patients // J. Clin. Microbiol. 2021. Vol. 59, No. 12. P. e0144721. DOI: 10.1128/JCM.01447-21

[9] Asherova IK, Kapranov NI. Mukoviscidoz — mediko-social’naya problema. Moscow; 2013. (In Russ.)

[10] Ашерова И.К., Капранов Н.И. Муковисцидоз — медико-социальная проблема. Москва, 2013.

[11] Mukoviscidoz. Ed. by N.I. Kapranov, N.Yu. Kashirskaya, E.I. Kondratieva. Moscow: Medpraktika-M; 2021. (In Russ.)

[12] Муковисцидоз / под ред. Н.И. Капранова, Н.Ю. Каширской, Е.И. Кондратьевой. Москва: ИД «Медпрактика-М», 2021.

[13] Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178. DOI: 10.1016/j.jcf.2018.02.006

[14] Castellani C., Duff A.J.A., Bell S.C. et al. ECFS best practice guidelines: the 2018 revision // J. Cyst. Fibros. 2018. Vol. 17, No. 2. P. 153–178. DOI: 10.1016/j.jcf.2018.02.006

[15] National Consensus “Cystic fibrosis: definitions, diagnostic criteria, therapy”. Ed. by E.I. Kondratieva, N.Yu. Kashirskaya, NI. Kapranov. Moscow; 2016. (In Russ.)

[16] Национальный консенсус «Муковисцидоз: определения, диагностические критерии, терапия» / под ред. Е.И. Кондратьевой, Н.Ю. Каширской, Н.И. Капранова. Москва, 2016.

[17] Chernuxa MYu, Avetisyan LR, Shaginyan IA, et al. Algorithm of microbiological diagnosis of chronic lung infection in patients with cystic fibrosis. Clinical Microbiology and Antimicrobial Chemotherapy. 2014;16(4);312–324. (In Russ.)

[18] Чернуха М.Ю., Аветисян Л.Р., Шагинян И.А. и др. Алгоритм микробиологической диагностики хронической инфекции легких у больных муковисцидозом // Клиническая микробиология и антимикробная химиотерапмя. 2014. Т. 16, № 4. С. 312–324.

[19] Baranov AA, Namazova-Baranova LS, Kutsev SI, et al. Modern approaches to the management of children with cystic fibrosis. Pediatric Pharmacology. 2022;19(2):153–195. (In Russ.). DOI: 10.15690/pf.v19i2.2417

[20] Баранов А.А., Намазова-Баранова Л.С., Куцев С.И. и др. Современные подходы к ведению детей с муковисцидозом // Педиатрическая фармакология. 2022. Т. 19, № 2. С. 153–195. DOI: 10.15690/pf.v19i2.2417

[21] Baranov AA, Namazova-Baranova LS, Kutsev SI, et al. Cystic fibrosis (cystic fibrosis). Clinical recommendations. Moscow; 2020. (In Russ.)

[22] Баранов А.А., Намазова-Баранова Л.С., Куцев С.И. и др. Кистозный фиброз (муковисцидоз). Клинические рекомендации. Москва, 2020.

[23] SP 158.13330.2014 Buildings and premises of medical organizations. Design rules (with Change N1). Clause 7.2.3.30 [Internet]. Available from: https://www.dokipedia.ru/document/ 5343846?pid=781. Accessed: Jun 2, 2022. (In Russ.)

[24] СП 158.13330.2014 Здания и помещения медицинских организаций. Правила проектирования (с Изменением № 1). Пп. 7.2.3.30 [Электронный ресурс]. Режим доступа: https://www.dokipedia.ru/document/5343846?pid=781. Дата обращения: 02.06.2022.

[25] Register of patients with cystic fibrosis in the Russian Federation. 2015. Ed. by E.I. Kondratieva, S.A. Krasovsky, A.Yu. Voronkova, et al. Moscow: Medpraktika-M; 2016. 72 p. (In Russ.)

[26] Регистр больных муковисцидозом в Российской Федерации. 2015 год / под ред. Е.И. Кондратьевой, С.А. Красовского, А.Ю. Воронковой и др. Москва, 2016.

[27] Register of patients with cystic fibrosis in the Russian Federation. 2017. Ed. by A.Y. Voronkova, E.L. Amelina, N.Yu. Kashirskaya, et al. Moscow: Medpraktika-M; 2019. 68 p. (In Russ.).

[28] Регистр больных муковисцидозом в Российской Федерации. 2017 год / под ред. А.Ю. Воронковой, Е.Л. Амелиной, Н.Ю. Каширской и др. Москва: ИД «Медпрактика-М», 2019. 68 с.

[29] Register of patients with cystic fibrosis in the Russian Federation. 2019. Ed. by N.Yu. Kashirskaya, E.I. Kondratieva, S.A. Krasovsky, et al. Moscow: Medpraktika-M; 2021. 68 p. (In Russ.)

[30] Регистр больных муковисцидозом в Российской Федерации. 2019 год / под ред. Н.Ю. Каширской, Е.И. Кондратьевой, С.А. Красовского и др. Москва: ИД «Медпрактика-М», 2021, 68 с

RIGHTS & PERMISSIONS

Eco-Vector